ArticleEndocrine2025
The monocyte/HDLc ratio and LDLc are two independent predictors of the response of Graves' ophthalmopathy patients to parenteral glucocorticoids.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGraves' ophthalmopathy (GO) is an inflammatory-autoimmune disease and parenteral glucocorticoids (IvGCs) are the first-line therapy in the moderate to severe forms. Oxidative stress (OX) and cholesterol have been related to severe forms and to the clinical outcome of GO. Recently some new biomarkers have been proposed as predictors of the clinical outcome in some cardiovascular and autoimmune diseases. We hypothesized that the monocyte-to-high-density lipoprotein cholesterol (HDL) ratio (MHR) could be a useful biomarker in GO management and aimed to evaluate the possible role of the MHR as a predictor of the clinical outcome in patients with active, moderate to severe GO treated with IvGCs.
methodsWe retrospectively studied 115 patients, 86 females and 29 males, with active, moderate to severe GO who were treated with IvGCs for 12 weeks at our institution. GO severity was evaluated according to EUGOGO suggestions, GO clinical activity and the clinical outcome of GO to IvGCs were evaluated by the seven-point Clinical Activity Score (CAS).
resultsThe baseline low density lipoproteins cholesterol (LDLc) and MHR were negatively and independently related to the improvement of GO at 12 weeks (p = 0.024 and p = 0.012, respectively). The value of the MHR = 0.0095 was identified as the best cut off by ROC curve and appeared to be a potentially useful tool to help identify patients with a poor response to IvGCs.
conclusionsThe MHR might be an useful tool to manage the immunosuppressant therapy in GO patients; our study confirms the role of LDLc as a predictor of GO outcome after IvGCs treatment.
Indexed as
Identifiers
39939523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.